Fusion Antibodies (LSE:FAB) Debt-to-Asset : 0.02 (As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Debt-to-Asset?

Fusion Antibodies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was £0.02 Mil. Fusion Antibodies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was £0.03 Mil. Fusion Antibodies's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was £2.06 Mil. Fusion Antibodies's debt to asset for the quarter that ended in Sep. 2023 was 0.02.

Fusion Antibodies Debt-to-Asset Historical Data

The historical data trend for Fusion Antibodies's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Debt-to-Asset Chart

Fusion Antibodies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Asset

Get a 7-Day Free Trial

0.02

0.06

0.04

0.01

0.04

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-Asset	Get a 7-Day Free Trial											0.03	0.01	0.08	0.04	0.02

Competitive Comparison of Fusion Antibodies's Debt-to-Asset

For the Biotechnology subindustry, Fusion Antibodies's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fusion Antibodies's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's Debt-to-Asset falls into.

Fusion Antibodies Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Fusion Antibodies's Debt-to-Asset for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.035	+	0.04)	/	2.062
	=	0.04

Fusion Antibodies's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.017	+	0.03)	/	2.058
	=	0.02

Fusion Antibodies (LSE:FAB) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Fusion Antibodies Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Antibodies (LSE:FAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL

Website

https://www.fusionantibodies.com

Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor • 10-21-2022